Ly Kieu La
Professor Ross
Intro to Pharm Tech
May 15, 2020
Assignment 8: Clinical Drug Trials of Remdesivir in treating
SAR CoV-2 patients
Group 1
1.
The Proposed indication for use of Remdesivir:
-
Interrupt virus reproduces
-
Block the virus from replicate into vitro
-
Activities against infection including acute respiratory symptom
2.
Qualification of participants in the study:
-
Participant with confirmed of SAR CoV-2 infection
-
Participant must be in 12 days of symptoms onset
-
Participant must do chest image with confirm pneumonia, and oxygen saturation of
94% or lower
3.
The length of the study:
-
21 days for Remdesivir group
-
23 days for placebo group
4.
Researcher/ organization:
-
Professor Bin Cao from China-Japan Friendship Hospital
-
Capital Medical University in China
5.
The benefits that are provided for participant:
-
Patient received standard care including lopinavir-ritonavir, interferons, and
corticosteroids.
Group 2
1.
The Proposed indication for use of Remdesivir:
-
Treatment for SARS-CoV-2
2.
Qualification of participants in the study:
-
Participant must have lab confirmed SARS-CoV-2 infection

Source link